Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine PCIA dose-ranging study after hysterectomy
ChiCTR2300068957Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Shihezi University
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in major depressive disorder (MDD) and postoperative pain (4 arms), sponsored by The First Affiliated Hospital of Shihezi University. Primary endpoint: Depression Assessment Scale. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2300068957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068957.